Elaldi 2009.
Methods | Historical control study | |
Participants | 218 confirmed cases, Mean age: ribavirin group mean 44.4 (SD = 19.1); No‐ribavirin group mean 40.9 (SD = 16.7), 50% women |
|
Interventions | Ribavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x daily for 6 days; Oral (nasogastric tube if oral not possible) | |
Outcomes | Mortality, length of hospital stay, requirement for transfusion (PRC, FFP, platelets) | |
Location and dates | Cumhuriyet University; Ankara Numune Training Hospital, Ataturk University Research Hospital; Ondokuz Mayis University, Sivas; Ankara; Erzurum; Samsun, Turkey tertiary centres 2004 | |
Number of days since onset of symptoms (mean/SD) | Median 5 (range = 1 ‐ 11) | |
Supportive therapy | Erythrocyte suspensions,platelet suspensions, FFP and other supportive as required | |
Notes |